查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835585

MRI导引神经外科消融市场（按类型、技术、应用和最终用户）—全球预测2025-2032

MRI Guided Neurosurgical Ablation Market by Type, Technology, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，MRI 引导的神经外科消融市场将成长至 60.2 亿美元，复合年增长率为 4.99%。

主要市场统计数据
基准年2024年 40.7亿美元
预计2025年 42.8亿美元
预测年份：2032年 60.2亿美元
复合年增长率（%） 4.99%

综合概述成像精度和能量传输的创新如何重新定义神经外科消融的实践模式和临床决策

MRI引导下的神经外科消融术是影像精度、热能和机械能传输以及微创技术的关键融合，正在重新定义颅内疾病的临床治疗路径。即时成像、能量调製和仪器微型化的进步使临床医生能够以毫米级精度进行靶向消融，同时最大限度地减少附带组织损伤。因此，患者选择标准、手术全期工作流程和跨学科协作模式正在不断发展，以获得诸如降低手术併发症发生率和加快患者康復等临床益处。

这项临床前景由涵盖多种适应症的不断扩展的依证塑造，并因器械人体工学、手术规划软体和术中监测的不断改进而进一步增强。这些发展支持从开放性切除术向影像引导的经皮和经颅介入治疗的转变，从而提高安全性和有效性。同时，更广泛的医疗环境——基于价值的采购、有限的资本预算以及对长期疗效的更严格审查——正在推动医疗机构采用可重复且能证明对患者有益的技术。

本引言将重点放在区分竞争治疗方法的技术属性、决定采用的临床重点以及影响采购的机构动态，从而为后续分析奠定基础。随后的总结将重点放在技术、临床和经济因素如何影响外科团队、医院系统和研究机构的决策。

影像、能量传输、机器人和人工智慧领域的创新如何重塑临床路径并加速微创神经外科切除术的采用

过去五年，MRI引导神经外科消融的技术基础设施和临床模式都发生了革命性的变化。高解析度术中MRI和改进的测温技术使能量输送系统能够以前所未有的精确度运行，改变了外科医生计算胼胝体病变风险和益处的方式。同时，聚焦能量治疗方法和雷射系统的成熟为先前被认为无法手术或开放性切除高风险的患者打开了新的治疗窗口。

同时，设备、软体和数位健康的融合正在加速。先进的治疗计画平台融合了机器学习辅助的分割和预测性热建模，从而实现病例模拟和个人化给药策略，从而减少术中不确定性。机器人引导和导航系统的整合正在标准化手术轨迹和植入定位，以提高不同外科医生和机构之间的可重复性。这些技术协同作用与简化围手术全期工作流程的程序创新相辅相成，从而提高了吞吐量，并实现了门诊或短期住院治疗的可能性。

临床上，向微创消融的转变改变了转诊模式和多学科协作。神经外科医生、神经肿瘤科医生、疼痛专家和功能神经外科医生越来越多地共同管理候选患者，促进方案化评估和共用决策。付款方和机构对比较结果的兴趣也日益浓厚，这导致他们更加重视註册登记、上市后监测和前瞻性证据的产生。总而言之，这些转变正在重新定义MRI引导消融的价值提案，并凸显了整合策略的重要性。

评估 2025 年美国关税对整个神经外科消融生态系统的设备采购、采购週期和服务模式的运作和策略影响

美国将于2025年加征累积关税，为从事MRI导引神经外科消融术的製造商、经销商和医疗保健提供者创造了新的商业环境。关税主导的成本压力已影响到进口组件和专用零件，例如雷射模组、精密光学元件和高规格电子产品，而这些零件对于消融平台的性能和可靠性至关重要。面对不断上升的投入成本，製造商正在评估筹资策略、重组供应商合同，在某些情况下，甚至加快本地化生产或寻找合格的替代组件供应商，以保持相当的设备性能。

医院和门诊中心的采购週期应对了更严格的资本配置，对整体拥有成本和服务合约的审查也更加严格。在资本采购谈判中，医疗保健机构优先考虑可预测的维护成本和耗材的批量定价，以缓解关税带来的波动。同时，一些供应商将其商业模式转向与绩效挂钩的服务合约和延长保固期，以保持竞争优势并应对预算限制。

由于跨境货物需要遵循新的海关程序和文件要求，监管和物流时间也受到了影响。临床试验申办者和研究机构的设备交货前置作业时间延长，迫使其调整入组时间表和临床试验硬体紧急时应对计画。投入成本上升、采购週期延长以及商业条款变化的综合影响，促使企业转向战略联盟、本地化製造外包，并追求模组化设备架构，以减少对关税敏感部件的依赖。这些调整正在塑造供应商的竞争力和组织在当前关税范围内的采购行为。

详细的細項分析揭示了产品类型、核心技术、临床适应症和最终用户偏好如何决定采用动态和策略性产品定位

細項分析揭示了不同设备类型、技术、应用和最终用户设定之间细微的采用和临床一致性，有助于制定差异化的产品和市场策略。按类型，本文研究了聚焦超音波、雷射消熔和射频消融术。聚焦超音波亚型分为高强度和低强度两种模式；雷射消熔进一步分为二极体和光纤雷射技术；射频消融术射频消融术则分为双极和单极两种配置。每种类型都具有独特的技术能力和临床权衡，这会影响其对特定病变特征和解剖限制的适用性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合机器学习演算法以提高 MRI 引导消融的准确性并减少附带组织损伤
  • 推出高场术中 MRI 套件，用于神经外科消融手术期间的高级即时成像
  • 引进机器人 MRI 导引导管导航系统，提升脑肿瘤消融的标靶精度
  • 开发云端基础的分析平台，用于汇总术后热感图和患者结果数据
  • 实施针对特定患者的 3D 列印脑部模型，用于雷射间质热疗消融术前规划

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. MRI导引神经外科消融市场（按类型）

  • 聚焦超音波
    • 高强度
    • 低强度
  • 雷射消熔
    • 二极体雷射
    • 光纤雷射
  • 射频消融
    • 双极
    • 单极

9. MRI导引神经外科消融市场（依技术）

  • 高强度聚焦超音波（HIFU）
  • 雷射间质热疗（LITT）

第 10 章 MRI 导引神经外科消融市场（按应用）

  • 脑肿瘤
    • 神经胶母细胞瘤
    • 脑膜瘤
    • 转移性肿瘤
  • 慢性疼痛
    • 坐骨神经痛
    • 三叉神经痛
  • 癫痫
    • 局部癫痫
    • 颞叶癫痫
  • 运动障碍
    • 肌张力不全症
    • 自发性震颤
    • 帕金森氏症

第 11 章。 MRI 导引神经外科消融市场（按最终用户）

  • 门诊手术中心
  • 医院
  • 研究机构

12. MRI导引神经外科消融市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章。 MRI 导引神经外科消融市场（按组）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. MRI导引神经外科消融市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Medtronic plc
    • Monteris Medical Corporation
    • INSIGHTEC Ltd
    • ClearPoint Neuro, Inc.
    • Siemens Healthineers AG
    • SternMed GmbH
    • Cook Group Incorporated
    • HCA International Limited
    • Ginger Healthcare Private Ltd.
    • Brown Neurosurgery
Product Code: MRR-036C5CF3A877

The MRI Guided Neurosurgical Ablation Market is projected to grow by USD 6.02 billion at a CAGR of 4.99% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.07 billion
Estimated Year [2025] USD 4.28 billion
Forecast Year [2032] USD 6.02 billion
CAGR (%) 4.99%

An integrated overview of how imaging precision and energy delivery innovations are redefining neurosurgical ablation practice patterns and clinical decision making

MRI guided neurosurgical ablation represents a pivotal convergence of imaging precision, thermal and mechanical energy delivery, and minimally invasive procedural techniques that are redefining clinical pathways for intracranial disease. Advances in real-time imaging, energy modulation, and instrument miniaturization now allow clinicians to perform targeted ablations with millimeter accuracy while minimizing collateral tissue injury. As a result, patient selection criteria, perioperative workflows, and interdepartmental collaboration models are evolving to capture the clinical benefits of reduced operative morbidity and faster recovery.

The clinical landscape is shaped by an expanding evidence base across multiple indications, augmented by iterative improvements in device ergonomics, procedural planning software, and intraoperative monitoring. These developments support a transition from open resections toward percutaneous and transcranial interventions that leverage imaging guidance to enhance safety and efficacy. Concurrently, the broader healthcare environment-characterized by value-based purchasing, constrained capital budgets, and intensified scrutiny of long-term outcomes-drives providers to adopt technologies that demonstrate reproducible, demonstrable patient benefit.

This introductory overview frames the remaining analysis by highlighting the technical attributes that differentiate competing modalities, the clinical priorities defining adoption, and the institutional dynamics that influence procurement. The synthesis that follows emphasizes how converging technological, clinical, and economic forces are shaping decision-making across surgical teams, hospital systems, and research institutions.

How converging innovations in imaging, energy delivery, robotics, and AI are reshaping clinical pathways and accelerating minimally invasive neurosurgical ablation adoption

The past five years have seen transformative shifts in both the technological underpinnings and the clinical framing of MRI guided neurosurgical ablation. High-resolution intraoperative MRI and improved thermometry methods have enabled energy delivery systems to operate with unprecedented precision, altering how surgeons weigh the risk-benefit calculus for lesions in eloquent brain regions. Simultaneously, the maturation of focused energy modalities and laser systems has opened new treatment windows for patients previously considered inoperable or high-risk for open resection.

Concurrently, convergence across device, software, and digital health domains has accelerated. Advanced treatment planning platforms now incorporate machine learning-assisted segmentation and predictive thermal modeling, enabling case simulation and personalized dosing strategies that reduce intraoperative uncertainty. Integration of robotic guidance and navigation systems has standardized trajectories and implant positioning, improving reproducibility across operators and sites. These technological synergies are complemented by procedural innovations that streamline perioperative workflows, enabling greater throughput and the potential for ambulatory or short-stay pathways.

Clinically, the shift toward minimally invasive ablation has changed referral patterns and multidisciplinary collaboration. Neurosurgeons, neuro-oncologists, pain specialists, and functional neurosurgeons increasingly co-manage candidates, promoting protocolized evaluation and shared decision-making. Payer and institutional attention to comparative outcomes is rising, prompting stronger emphasis on registries, post-market surveillance, and prospective evidence generation. Taken together, these shifts are redefining the value proposition of MRI guided ablation and elevating the importance of integrated clinical, regulatory, and commercial strategies.

Assessment of the operational and strategic effects that the 2025 United States tariffs have imposed on device sourcing, procurement cycles, and service models across the neurosurgical ablation ecosystem

The imposition of cumulative tariffs in the United States in 2025 introduced new operating conditions for manufacturers, distributors, and healthcare providers engaged in MRI guided neurosurgical ablation. Tariff-driven cost pressure has affected imported subassemblies and specialty components-such as laser modules, precision optics, and high-specification electronics-that are central to the performance and reliability of ablation platforms. Manufacturers faced with increased input costs have evaluated sourcing strategies, reconfigured supplier contracts, and in some cases accelerated efforts to localize production or qualify alternative component suppliers to preserve parity in device performance.

Procurement cycles at hospitals and ambulatory centers responded to tighter capital allocation by intensifying scrutiny of total cost of ownership and service agreements. Institutions negotiating capital purchases prioritized predictable maintenance expenses and bundled consumable pricing to mitigate the variability introduced by tariffs. In parallel, some suppliers shifted commercial models toward outcome-linked service contracts and extended warranties to maintain competitive advantage and accommodate budgetary constraints.

Regulatory and logistics timelines were also affected as cross-border shipments navigated new customs processes and documentation requirements. For clinical trial sponsors and research institutes, extended lead times for device delivery necessitated adjustments to enrollment schedules and contingency planning for trial hardware. The combined effect of higher input costs, longer procurement timelines, and altered commercial terms has incentivized strategic collaborations, contract manufacturing localization, and the pursuit of modular device architectures that reduce dependence on tariff-sensitive components. These adaptations are shaping supplier competitiveness and institutional procurement behavior beyond the immediate tariff window.

Deep segmentation analysis revealing how device types, core technologies, clinical indications, and end-user settings determine adoption dynamics and strategic product positioning

Segmentation analysis reveals nuanced adoption and clinical alignment across device types, technologies, applications, and end-user settings, informing differentiated product and market strategies. Based on Type, the landscape is studied across Focused Ultrasound, Laser Ablation, and Radiofrequency Ablation; the Focused Ultrasound subtypes divide into High Intensity and Low Intensity modalities; Laser Ablation further differentiates into Diode Laser and Fiber Laser technologies; and Radiofrequency Ablation is examined in Bipolar and Monopolar configurations. Each type presents distinct technical capabilities and clinical trade-offs that influence suitability for specific lesion characteristics and anatomical constraints.

Based on Technology, the market analysis contrasts High-Intensity Focused Ultrasound (HIFU) with Laser Interstitial Thermal Therapy (LITT), emphasizing differences in energy deposition dynamics, thermal spread, and compatibility with concurrent MRI thermometry. The technical distinctions between HIFU and LITT translate into divergent procedural workflows, patient preparation requirements, and infrastructure implications, thereby affecting institutional adoption patterns.

Based on Application, the clinical segmentation covers Brain Tumors, Chronic Pain, Epilepsy, and Movement Disorders; within Brain Tumors, the focus includes Glioblastoma, Meningioma, and Metastatic Tumors; Chronic Pain is examined with attention to Sciatica and Trigeminal Neuralgia; Epilepsy analysis separates Focal Epilepsy and Temporal Lobe Epilepsy; and Movement Disorders are considered across Dystonia, Essential Tremor, and Parkinson's Disease. These application-level distinctions are critical because therapeutic intent, required precision, acceptable thermal margins, and outcome metrics differ substantially between oncologic and functional indications.

Based on End User, adoption dynamics vary across Ambulatory Surgical Centers, Hospitals, and Research Institutes, each of which demands tailored service models and capital strategies. Hospitals tend to prioritize robustness, multi-disciplinary applicability, and comprehensive service coverage, whereas ambulatory centers emphasize throughput efficiency and simplified logistical requirements, and research institutes prioritize flexibility for protocol testing and instrumentation modifications. Together, these segmentation insights indicate that successful market players align product design, clinical evidence generation, and commercial engagement to the specific technical and institutional requirements of the segment they target.

Comparative regional evaluation showing how regulatory, reimbursement, clinical infrastructure, and localization strategies drive differentiated adoption patterns across global markets

Regional dynamics for MRI guided neurosurgical ablation reveal distinct opportunity spaces and operational constraints shaped by regulatory regimes, reimbursement environments, clinical infrastructure, and research investment. In the Americas, centers of excellence concentrated in tertiary hospitals and research networks are early adopters of image-guided ablation technologies, supported by active clinical trial activity and an emphasis on comparative effectiveness studies. Payment structures and regional variations in capital allocation influence the pace of diffusion, while strong clinical advocacy and surgeon-led initiatives drive referrals for complex indications.

In Europe, Middle East & Africa, the landscape is heterogeneous; Western European markets show mature regulatory frameworks and established specialist centers that integrate ablation into multidisciplinary care pathways, whereas emerging markets within the region experience uneven access to imaging infrastructure and variable reimbursement policies. Consequently, manufacturers and clinical partners often pursue phased introductions, leveraging clinical partnerships and outcomes data to expand utilization. Investment in training and clinician networks is particularly important to overcome procedural learning curves and standardize care pathways across geographically dispersed institutions.

In Asia-Pacific, rapid infrastructure expansion, rising research investment, and an increasing focus on minimally invasive interventions create fertile ground for adoption, but market entry strategies must account for diverse regulatory requirements, localized procurement preferences, and differing payer expectations. Regional manufacturing and service localization strategies can accelerate acceptance, especially where tariff or logistics considerations affect component availability. Across all regions, collaborative trials, local key opinion leader engagement, and tailored reimbursement strategies materially influence the rate at which new technologies become integrated into routine practice.

How industry participants are using clinical evidence, software ecosystems, strategic partnerships, and resilient supply chains to establish sustainable competitive advantage

Competitive behavior among companies operating in the MRI guided neurosurgical ablation landscape is characterized by a focus on clinical differentiation, technology integration, and service models that prioritize total procedural value. Leading firms invest heavily in clinical evidence programs that demonstrate procedural safety, functional outcomes, and quality-of-life improvements for selected indications, recognizing that robust data is a primary determinant of hospital procurement decisions and payer support. Beyond evidence generation, companies concentrate on strengthening their software ecosystems-treatment planning, thermometry visualization, and outcome tracking-to create high switching costs and embed their platforms within clinical workflows.

Strategic partnerships with imaging and navigation vendors, academic centers, and specialized service providers have become common as companies seek to de-risk development and accelerate clinical adoption. Business models increasingly combine capital equipment sales with recurring revenue streams from disposables, software subscriptions, and extended service agreements. Attention to post-market surveillance and registry participation underscores a commitment to continuous safety monitoring and clinical improvement.

From an operational perspective, firms are optimizing supply chains and manufacturing footprints to mitigate geopolitical and tariff-related risk, as well as investing in scalable training programs to shorten the learning curve for new adopters. Competitive differentiation also arises from approaches to device modularity and interoperability, enabling integration into heterogeneous IT and imaging environments. Collectively, these company-level strategies indicate that long-term competitive advantage will accrue to organizations that align clinical value, operational resilience, and partner-enabled ecosystems.

Practical strategic moves for manufacturers and providers to accelerate adoption through evidence generation, platform differentiation, resilient supply chains, and tailored commercial models

Industry leaders should prioritize a coordinated set of tactical and strategic actions to capture clinical and commercial value as neurosurgical ablation technologies evolve. First, invest in indication-specific evidence generation that aligns clinical endpoints with payer and hospital decision criteria; prospective registries and randomized or comparative effectiveness studies will materially strengthen the value proposition for surgical teams and procurement committees. Second, build integrated digital tools for treatment planning, intraoperative monitoring, and outcomes tracking to enhance clinician productivity and create platform differentiation that extends beyond the hardware purchase.

Third, consider supply chain diversification and localized manufacturing partnerships to reduce exposure to tariff volatility and logistics disruptions; modular product architectures and qualified secondary suppliers for critical components can shorten lead times and stabilize service commitments. Fourth, tailor commercial models to end-user economics: offer financing, bundled service agreements, and outcome-linked pricing alternatives to address the capital constraints and reimbursement complexities of hospitals and ambulatory centers. Fifth, invest in comprehensive training and proctoring programs-delivered through a mix of in-person and virtual simulation-to accelerate adoption while protecting patient safety.

Finally, engage early with payers and health technology assessment bodies to align evidence generation with reimbursement needs, and pursue strategic clinical partnerships with academic centers to catalyze broader clinical acceptance. Executed together, these actions will position companies and provider organizations to translate technological promise into sustainable clinical adoption and institutional value.

Transparent multi-method research approach combining clinical expert interviews, device technical assessment, regulatory review, and supply chain analysis to validate insights and recommendations

The research underpinning this executive summary synthesizes qualitative and quantitative inputs derived from a structured blend of primary and secondary investigation techniques designed for triangulation and validation. Primary research included in-depth interviews with clinical experts across neurosurgery, neuro-oncology, pain management, and functional neurosurgery, as well as discussions with procurement leaders, clinical engineers, and research institute directors to capture practical deployment considerations and procurement behavior. Manufacturer interviews and targeted supplier consultations provided insight into technology roadmaps, manufacturing constraints, and service model evolution.

Secondary inputs comprised peer-reviewed clinical literature, regulatory guidance documents, procedural standards, and trial registries to assemble a comprehensive picture of safety, efficacy, and procedural protocols. Technical assessment incorporated device specifications, imaging integration requirements, and interoperability considerations derived from product documentation and engineering analyses. Supply chain and tariff impact analysis relied on customs regimes, import classifications, and publicly available trade policy summaries to evaluate potential operational effects.

Data synthesis employed iterative validation steps, reconciling divergent viewpoints through follow-up interviews and cross-referencing technical claims against clinical outcomes evidence. The methodology prioritized transparency in assumptions, careful separation of observed facts from expert opinion, and clear documentation of data sources to support reproducibility and to inform subsequent deep-dive investigations customized for specific strategic questions.

A concise synthesis of the strategic imperatives and collaborative priorities required to translate MRI guided ablation innovations into sustained clinical and commercial impact

MRI guided neurosurgical ablation stands at the intersection of rapid technological progress and evolving clinical practice, offering meaningful potential to improve patient outcomes while introducing new operational and commercial complexities. The collective trends-advances in imaging and thermometry, software-enabled planning, and shifting clinical pathways-signal a durable movement toward less invasive intracranial interventions that demand coordinated strategies from device manufacturers, healthcare providers, and policy stakeholders. Realizing the promise of these technologies requires investment in robust clinical evidence, adaptable commercial models, and resilient operational practices that can withstand geopolitical and supply chain variability.

Looking ahead, the ability of organizations to integrate clinical insights with pragmatic service offerings will determine adoption trajectories across applications and regions. Collaboration among device makers, imaging partners, clinician networks, and payers will be essential to create standardized pathways, accelerate training, and align reimbursement with demonstrated outcomes. As stakeholders navigate regulatory nuances, procurement constraints, and evolving clinical expectations, those that adopt a patient-centered, evidence-driven approach will be best positioned to convert technological capability into measurable improvements in care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of machine learning algorithms to enhance MRI guided ablation precision and reduce collateral tissue damage
  • 5.2. Deployment of high-field intraoperative MRI suites for advanced real-time imaging during neurosurgical ablation procedures
  • 5.3. Adoption of robot-assisted MRI guided catheter navigation systems for improved targeting accuracy in brain tumor ablation
  • 5.4. Development of cloud-based analytics platforms for aggregating postoperative thermal mapping and patient outcome data
  • 5.5. Implementation of patient-specific 3D printed brain phantoms for preoperative planning of laser interstitial thermal therapy ablation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. MRI Guided Neurosurgical Ablation Market, by Type

  • 8.1. Focused Ultrasound
    • 8.1.1. High Intensity
    • 8.1.2. Low Intensity
  • 8.2. Laser Ablation
    • 8.2.1. Diode Laser
    • 8.2.2. Fiber Laser
  • 8.3. Radiofrequency Ablation
    • 8.3.1. Bipolar
    • 8.3.2. Monopolar

9. MRI Guided Neurosurgical Ablation Market, by Technology

  • 9.1. High-Intensity Focused Ultrasound (HIFU)
  • 9.2. Laser Interstitial Thermal Therapy (LITT)

10. MRI Guided Neurosurgical Ablation Market, by Application

  • 10.1. Brain Tumors
    • 10.1.1. Glioblastoma
    • 10.1.2. Meningioma
    • 10.1.3. Metastatic Tumors
  • 10.2. Chronic Pain
    • 10.2.1. Sciatica
    • 10.2.2. Trigeminal Neuralgia
  • 10.3. Epilepsy
    • 10.3.1. Focal Epilepsy
    • 10.3.2. Temporal Lobe Epilepsy
  • 10.4. Movement Disorders
    • 10.4.1. Dystonia
    • 10.4.2. Essential Tremor
    • 10.4.3. Parkinson's Disease

11. MRI Guided Neurosurgical Ablation Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Research Institutes

12. MRI Guided Neurosurgical Ablation Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. MRI Guided Neurosurgical Ablation Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. MRI Guided Neurosurgical Ablation Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Medtronic plc
    • 15.3.2. Monteris Medical Corporation
    • 15.3.3. INSIGHTEC Ltd
    • 15.3.4. ClearPoint Neuro, Inc.
    • 15.3.5. Siemens Healthineers AG
    • 15.3.6. SternMed GmbH
    • 15.3.7. Cook Group Incorporated
    • 15.3.8. HCA International Limited
    • 15.3.9. Ginger Healthcare Private Ltd.
    • 15.3.10. Brown Neurosurgery

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MRI GUIDED NEUROSURGICAL ABLATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MRI GUIDED NEUROSURGICAL ABLATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MRI GUIDED NEUROSURGICAL ABLATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH INTENSITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LOW INTENSITY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DIODE LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FIBER LASER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER INTERSTITIAL THERMAL THERAPY (LITT), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY GLIOBLASTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MENINGIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY METASTATIC TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SCIATICA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCAL EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TEMPORAL LOBE EPILEPSY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY DYSTONIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY ESSENTIAL TREMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY PARKINSON'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY BRAIN TUMORS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY CHRONIC PAIN, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY EPILEPSY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY MOVEMENT DISORDERS, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY FOCUSED ULTRASOUND, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY LASER ABLATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY RADIOFREQUENCY ABLATION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA MRI GUIDED NEUROSURGICAL ABLATION MARKET SIZE, BY AP